Chen Shi, Cong Wang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, . . . Yu Zhang. (2024). Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway. Elsevier.
Chicago Style (17th ed.) CitationChen Shi, Cong Wang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Zhang, Shijun Li, and Yu Zhang. Lipocalin 2 (LCN2) Confers Acquired Resistance to Almonertinib in NSCLC Through LCN2-MMP-9 Signaling Pathway. Elsevier, 2024.
MLA (9th ed.) CitationChen Shi, et al. Lipocalin 2 (LCN2) Confers Acquired Resistance to Almonertinib in NSCLC Through LCN2-MMP-9 Signaling Pathway. Elsevier, 2024.
Warning: These citations may not always be 100% accurate.